|Podcasts|August 2, 2018

Episode 14: Emerging Biotech in NYC

Nancy Thornberry, CEO of Kallyope, talks with Michelle Maskaly and Christen Harm about New York City as an emerging hotspot for biotech incubators, and the challenges and opportunities related to space, location, recruitment, and funding.

Nancy Thornberry, CEO of Kallyope, talks with Michelle Maskaly and Christen Harm about New York City as an emerging hotspot for biotech incubators, and the challenges and opportunities related to space, location, recruitment, and funding.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 

 


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.